SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-21-056458
Filing Date
2021-09-16
Accepted
2021-09-16 18:14:31
Documents
2
Period of Report
2021-09-14

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1541
2 POA DOCUMENT poa.txt EX-24.3_1008808 3057
  Complete submission text file 0001209191-21-056458.txt   6300
Mailing Address C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO CA 92130
Business Address
Brinkley Ruth Williams (Reporting) CIK: 0001344381 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36257 | Film No.: 211258830

Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Issuer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations